Roche/Genentech/Chugai's Herceptin as an add-on to standard chemotherapy will become decision resources' clinical gold standard in 2013 for the treatment of gastric cancer

WALTHAM, Mass. - Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ ...

read more

Lonza announces alliance with Odyssey Thera

BASEL, Switzerland – Lonza announced today the signing of an agreement with Odyssey Thera, Inc. to make Odyssey Thera’s proprietary Protein-fragment Complementation Assay technology, as part of compou...

read more

Roche’s MabThera on the brink of NICE green light for leukaemia

The National Institute for Health and Clinical Excellence has published final recommendations for the use of Roche’s MabThera as a treatment for leukaemia on the National Health Service

read more

Helge Grosshans receives ERC grant for his microRNA research

Helge Grosshans, group leader at the Friedrich Miescher Institute for Biomedical Research, has received the European Research Council (ERC) Starting Independent Researcher Grant. This very competitive...

read more

Bringing statistics to biologists - new Genedata analyst launches at Society of Toxicology 49th annual meeting

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced Genedata Analyst™, an integrated statistical and data analysis platform with a...

read more

Bayer CropScience and Mendel Biotechnology expand collaboration in crop protection

MONHEIM – Bayer CropScience and Mendel Biotechnology, Inc. in Hayward, California (USA) have entered into a new three-year collaboration agreement which extends their existing joint activities.

read more

Epistem posts profit thanks to Novartis deal

Manchester-based biotech company Epistem (AIM: EHP) today posted a first-half pre-tax profit thanks to a boost from the group's collaboration with big pharma group Novartis.

read more

Agilent on road to recovery

Following stellar results in the fiscal first quarter ended January 2010, Agilent Technologies’ (A - Analyst Report) CFO, Adrian Dillon, has left the company.

read more

Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold

Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme.

read more

Life Technologies, TGen and US oncology partner on groundbreaking breast cancer sequencing research

CARLSBAD, Calif., PHOENIX & THE WOODLANDS, Texas - LifeTechnologies Corporation (NASDAQ:LIFE) today announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US ...

read more

Santhera reports strong 2009 revenues of CHF 22.3m and is financed beyond 2011

LIESTAL, Switzerland - Santhera Pharmaceuticals (SIX: SANN) announced today the financial results for 2009 and updated on the development pipeline.

read more

Actelion announces Full year 2009 financial results

ALLSCHWIL/BASEL, Switzerland - Actelion Ltd (SIX: ATLN) today announced its financial results for the full year 2009. With total net revenues CHF1,772.6 million (FY 2008: CHF 1,473.5 m) and operating ...

read more

Basilea strikes licensing deal with Astellas

ZURICH - Swiss biotech Basilea struck a licensing deal with Japan's Astellas Pharma, bringing in an upfront payment of 75 million Swiss francs ($70 million) to help ease its cash shortage.

read more

Roche study drug may offer valuable new treatment option for patients with type 2 diabetes

Roche announced today that results from the first five Phase III clinical trials show that taspoglutide has met the primary end-points of reduction in blood glucose (blood sugar) in these studies. Roc...

read more

Clariant slashes hundreds of jobs in Switzerland

The Clariant specialty chemicals group announced a loss for 2009 on Tuesday and said it would cut 500 jobs, 400 of them in Switzerland.

read more

Novartis oral multiple sclerosis development compound Gilenia (FTY720) granted US priority review status

BASEL, Switzerland - Gilenia®* (FTY720, fingolimod) has been granted priority review status by the US Food and Drug Administration (FDA), which accepted the regulatory submission made in December 2009...

read more

Galapagos and MorphoSys expand antibody alliance

MECHELEN, Belgium and MARTINSRIED/MUNICH, Germany - Galapagos NV (Euronext: GLPG) and MorphoSys AG (FSE: MOR) announce that they have expanded their antibody alliance in bone & joint diseases.

read more

Roche collaborates with Merck on developmental test for cancer-related gene mutation

PLEASANTON, Calif - Roche Molecular Systems, Inc. (SIX: RO, ROG; OTCQX: RHHBY) announced today a research collaboration with Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.) providing Mer...

read more

RIKEN Center for Genomics Medicine chooses Genedata Expressionist for high throughput proteomics R&D

BASEL, Switzerland and TOKJO, Japan - Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that the Japanese research foundation RI...

read more

Polyphor discovers a new class of antibiotics with a novel mode of action

ALLSCHWIL, Switzerland - Today, Polyphor Ltd published the discovery of a new class of antibiotics with a novel mode of action (Science, VOL 327, ISSUE 5968). This proprietary new class of antibiotics...

read more